Mode
Text Size
Log in / Sign up
Phase 4 Completed N=62 Randomized Double-blind Supportive Care

Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors

Pituitary Tumor · Postoperative Pain
Source: ClinicalTrials.gov NCT02351700 ↗
Enrolled (actual)
62
Serious AEs
3.2%
Results posted
Oct 2021
Primary outcomePrimary: Comparison of Mean Pain Scores Between Two Arms (Measured Every 4 Hours Over 48 Hour) — 1.7; 2.8 0-10 units on a scale
◆ Published Evidence
Established
42citations · ~5 / year
Randomized, double-blinded, placebo-controlled trial comparing two multimodal opioid-minimizing pain management regimens following transsphenoidal surgery.
Journal of neurosurgery · 2018 · Open access · High-confidence link

Summary

A randomized, double-blind, placebo-controlled intervention trial involving 100 treated subjects undergoing endonasal trans-sphenoidal (ENTS) resection of pituitary lesion. Subjects will be randomized into two groups: 50 treated in the opioid-sparing arm and 50 treated in the standard post-operative medication arm.

Linked Publications

  • Randomized, double-blinded, placebo-controlled trial comparing two multimodal opioid-minimizing pain management regimens following transsphenoidal surgery.
    Journal of neurosurgery · 2018 · 42 citations · Open access · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Comparison of Mean Pain Scores Between Two Arms (Measured Every 4 Hours Over 48 Hour)
1.7; 2.8
SECONDARY
Breakthrough Narcotic Requirement
26.3; 62.5
SECONDARY
Other Adverse Events
0; 2

Eligibility Criteria

Inclusion Criteria

  • Adult patient undergoing ENTS surgery for resection of pituitary tumor.
  • Adults >18 years and 19 and 2.0
  • Allergy or intolerance to acetaminophen, ibuprofen, or opioids
  • Pre-operative opioid tolerance, dependence, or abuse
  • Anaphylaxis to opioids
  • History of peptic ulcer disease or recent gastrointestinal bleed requiring surgery
  • Cirrhosis, hepatitis, liver transplant, or liver function studies out of normal range, defined as aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/bilirubin> 3x upper limit of normal range
  • Subject unwilling or unable to sign informed consent for the study
  • Pregnancy
  • Incarcerated patients
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02351700) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search